Crypto · News reference
Mistras Group, Strategy, Hyperliquid Strategies And Other Big Stocks Moving Higher On Friday
U.S. stocks were mixed as the Dow fell 150 points; Mistras surged on a $20.35/share buyout deal, while crypto and tech stocks gained.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Shares of software companies are trading lower as elevated oil prices and stronger-than-expected inflation data fuel expectations of more Fed tightening at a quicker pace. Costlier borrowing may weaken sentiment for the sector's strong H2 2026 rally.
Maxim Group Maintains Buy on American Bitcoin, Raises Price Target to $16
Maxim Group analyst Matthew Garland maintains American Bitcoin (NASDAQ:ABTC) with a Buy and raises the price target from $15 to $16.
First Tracks Biotherapeutics, C3.ai, CCC Intelligent Solutions And Other Big Stocks Moving Higher On Monday
U.S. stocks mixed; First Tracks Biotherapeutics surged 18% on positive celiac trial results, while C3.ai, Liquidia and others also gained.
Reported Earlier, Alamar Biosciences' Precision Proteomics Platform Enables Lancet Neurology Study Showing Alzheimer's Patients Exhibit Markedly Different Biological Responses During Anti-Amyloid Antibody Treatment With Lecanemab
Lancet Neurology Study Using Alamar Biosciences’ Technology Reveals Divergent Biological Responses to Alzheimer’s Treatment
A longitudinal study published in The Lancet Neurology using Alamar Biosciences' NULISAseq CNS 120 panel found that patients receiving lecanemab for early symptomatic Alzheimer's disease show markedly different biological responses. The research revealed that biomarkers associated with amyloid clearance differ from those associated with cognitive decline, explaining why clearing amyloid doesn't produce uniform clinical benefits across patients. The study measured 130 plasma proteins across 2,385 samples from 1,967 participants.